Biologics have increased in prevalence and value in the global marketplace and have continued to become more complex, both by modality and by delivery.
The potential for computational tools to add tangible value to the development of biologics is huge, yet this potential remains largely untapped. CDD for Biologics is dedicated to harnessing the power of in silico tools, to de-risk drug development from early drug discovery through to late preclinical development.
Building upon the framework and success of its inaugural meeting, we will once again gather computational thought leaders in pharma, academia and software providers along with the end-users in computational and structural biology to debate how best to add immediate value to biologics pipelines.
Through sharing novel insights from our industry leading faculty, we will explore how best to add immediate value to biologics pipelines.
Discuss how to improve predictability of target ID and validation, understand protein/protein interactions, enhance rational candidate selection, and optimize developability characteristics.
The potential for computational tools to add tangible value to the development of biologics is huge, yet this potential remains largely untapped. CDD for Biologics is dedicated to harnessing the power of in silico tools, to de-risk drug development from early drug discovery through to late preclinical development.
Building upon the framework and success of its inaugural meeting, we will once again gather computational thought leaders in pharma, academia and software providers along with the end-users in computational and structural biology to debate how best to add immediate value to biologics pipelines.
Through sharing novel insights from our industry leading faculty, we will explore how best to add immediate value to biologics pipelines.
Discuss how to improve predictability of target ID and validation, understand protein/protein interactions, enhance rational candidate selection, and optimize developability characteristics.
